(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 27.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.71%.
Valneva Se's revenue in 2025 is $228,288,372.On average, 1 Wall Street analysts forecast VALN's revenue for 2025 to be $35,217,457,226, with the lowest VALN revenue forecast at $35,217,457,226, and the highest VALN revenue forecast at $35,217,457,226. On average, 1 Wall Street analysts forecast VALN's revenue for 2026 to be $44,534,184,704, with the lowest VALN revenue forecast at $44,534,184,704, and the highest VALN revenue forecast at $44,534,184,704.
In 2027, VALN is forecast to generate $80,680,553,926 in revenue, with the lowest revenue forecast at $80,680,553,926 and the highest revenue forecast at $80,680,553,926.